Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1633]

Azacitidine plus nivolumab against acute myeloid leukaemia

Prof Naval Daver - MD Anderson Cancer Center, Houston, USA

Azacitidine plus nivolumab against acute myeloid leukaemia ( Prof Naval Daver - MD Anderson Cancer Center, Houston, USA )

How can we use crenolanib to treat AML?

Dr Eunice Wang - Roswell Park Cancer Institute, New York, USA

How can we use crenolanib to treat AML? ( Dr Eunice Wang - Roswell Park Cancer Institute, New York, USA )

Highlights in myeloid leukaemia research from ASH 2016

Dr Luca Mazzarella - European Institute of Oncology, Milan, Italy

Highlights in myeloid leukaemia research from ASH 2016 ( Dr Luca Mazzarella - European Institute of Oncology, Milan, Italy )

Thromboembolytic risks of central venous catheters in paediatric patients

Dr Julie Jaffray - Children's Center for Cancer, Los Angeles, USA

Thromboembolytic risks of central venous catheters in paediatric patients ( Dr Julie Jaffray - Children's Center for Cancer, Los Angeles, USA )

Pure erythroid leukaemias

Dr Guillermo Montalbán Bravo - MD Anderson Cancer Center, Houston, USA

Pure erythroid leukaemias ( Dr Guillermo Montalbán Bravo - MD Anderson Cancer Center, Houston, USA )

Clinical updates for guadecitabine and vorinostat

Dr Guillermo Montalbán Bravo - MD Anderson Cancer Center, Houston, USA

Clinical updates for guadecitabine and vorinostat ( Dr Guillermo Montalbán Bravo - MD Anderson Cancer Center, Houston, USA )

ALL: Combining paediatric-type therapy with minimal residual disease

Dr Alessandro Rambaldi - Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

ALL: Combining paediatric-type therapy with minimal residual disease ( Dr Alessandro Rambaldi - Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy )

Pracinostat and azacitidine for elderly AML

Prof Guillermo Garcia-Manero - MD Anderson Cancer Center, Houston, USA

Pracinostat and azacitidine for elderly AML ( Prof Guillermo Garcia-Manero - MD Anderson Cancer Center, Houston, USA )

ASH 2016: AML, CLL and leukaemogenesis latest

Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA

ASH 2016: AML, CLL and leukaemogenesis latest ( Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA )

Ineligibility required for 'anti-trials': inclusion in studies regardless of...

Prof Guillermo Garcia-Manero - MD Anderson Cancer Center, Houston, USA

Ineligibility required for 'anti-trials': inclusion in studies regardless of fitness ( Prof Guillermo Garcia-Manero - MD Anderson Cancer Center, Houston, USA )

Vosaroxin for relapsed AML: Updates from VALOR

Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA

Vosaroxin for relapsed AML: Updates from VALOR ( Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA )

Impact of next-generation sequencing on treatment choice for MDS

Dr Ana Alfonso Pierola - MD Anderson Cancer Center, Houston, USA

Impact of next-generation sequencing on treatment choice for MDS ( Dr Ana Alfonso Pierola - MD Anderson Cancer Center, Houston, USA )

More from ecancer